The effect of low-dose colchicine in patients with stable coronary artery disease: The LoDoCo2 trial rationale, design, and baseline characteristics-Reference-Cited by-同舟云学术

The effect of low-dose colchicine in patients with stable coronary artery disease: The LoDoCo2 trial rationale, design, and baseline characteristics

Published:2019-12 Issue: Volume:218 Page:46-56
ISSN:0002-8703
Container-title:American Heart Journal
language:en
Short-container-title:American Heart Journal

Author:

Nidorf Stefan M,Fiolet Aernoud T. L,Eikelboom John W,Schut Astrid,Opstal Tjerk S. J,Bax Willem A,Budgeon Charley A,Tijssen Jan G. P,Mosterd Arend,Cornel Jan H,Thompson Peter L

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference64 articles.

1. Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label;Ueki;randomised controlled trial Lancet Diabetes Endocrinol,2017

2. Ezetimibe added to statin therapy after acute coronary syndromes;Cannon;N Engl J Med,2015

3. Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681. doi:https://doi.org/10.1016/S0140-6736(10)61350-5

4. Alirocumab and cardiovascular outcomes after acute coronary syndrome;Schwartz;N Engl J Med,2018

5. Effect of intensive blood-pressure treatment on patient-reported outcomes;Berlowitz;N Engl J Med,2017

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Beyond LDL-C: unravelling the residual atherosclerotic cardiovascular disease risk landscape—focus on hypertriglyceridaemia;Frontiers in Cardiovascular Medicine;2024-08-07

2. Therapeutic potentials of peptide-derived nanoformulations in atherosclerosis: present status and future directions;International Journal of Smart and Nano Materials;2024-07-02

3. A systematic review on the use of Colchicine in Hemorrhagic Stroke;World Neurosurgery: X;2024-07

4. Emerging insights into the role of IL-1 inhibitors and colchicine for inflammation control in type 2 diabetes;Diabetology & Metabolic Syndrome;2024-06-25

5. A novel VCP modulator, KUS121, attenuates atherosclerosis progression by maintaining intracellular ATP and mitigating ER stress in endothelial cells;2024-05-02